Agios Pharmaceuticals (AGIO) EBITDA (2012 - 2026)

Agios Pharmaceuticals has reported EBITDA for 15 years, with the latest figure at -$110.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 3.18% year-over-year to -$110.0 million; the trailing twelve-month figure through Mar 2026 stood at -$475.5 million (down 8.0% YoY), and the FY2025 full-year result was -$472.1 million, down 10.9% from the prior year.
• EBITDA for Q1 2026 stood at -$110.0 million, up from -$121.6 million in the prior quarter.
• The five-year high for EBITDA was -$90.6 million in Q1 2023, with the low at -$127.1 million in Q2 2025.
• Historically, EBITDA has averaged -$105.2 million across 5 years, with a median of -$102.8 million in 2024.
• Annual changes were most pronounced in 2022 — EBITDA slumped 105.4% — and 2023, when it climbed 10.41%.
• Agios Pharmaceuticals' EBITDA stood at -$99.2 million in 2022, then dropped by 7.16% to -$106.3 million in 2023, then slipped by 17.65% to -$125.0 million in 2024, then advanced by 2.77% to -$121.6 million in 2025, then climbed by 9.5% to -$110.0 million in 2026.
• The last three EBITDA figures came in at -$110.0 million (Q1 2026), -$121.6 million (Q4 2025), and -$116.9 million (Q3 2025), per Business Quant data.